^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
KITE-363
i
Other names: KITE-363, KITE363, KITE 363
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Gilead
Drug class:
CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy
Related drugs:
7ms
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov)
P2, N=700, Enrolling by invitation, Kite, A Gilead Company | Trial completion date: Mar 2041 --> Dec 2040 | Trial primary completion date: Mar 2041 --> Dec 2040
Trial completion date • Trial primary completion date
|
Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • KITE-222 • KITE-363 • KITE-439 • KITE-585 • KITE-718
8ms
KT-US-499-0150: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (clinicaltrials.gov)
P1, N=114, Recruiting, Kite, A Gilead Company | Trial completion date: Jan 2027 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
cyclophosphamide • fludarabine IV • KITE-363
9ms
KT-US-499-0150: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (clinicaltrials.gov)
P1, N=114, Recruiting, Kite, A Gilead Company | Trial completion date: Jan 2041 --> Jan 2027 | Trial primary completion date: Apr 2024 --> Jul 2025
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
cyclophosphamide • fludarabine IV • KITE-363
over1year
KT-US-499-0150: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (clinicaltrials.gov)
P1, N=114, Recruiting, Kite, A Gilead Company | N=80 --> 114
Enrollment change • CAR T-Cell Therapy
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • CSF2 (Colony stimulating factor 2) • GZMB (Granzyme B) • GZMA (Granzyme A) • IL17A (Interleukin 17A) • IL15 (Interleukin 15) • IL1R1 (Interleukin 1 receptor, type I) • IL7 (Interleukin 7) • CRP (C-reactive protein)
|
cyclophosphamide • fludarabine IV • KITE-363
over1year
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov)
P2, N=700, Enrolling by invitation, Kite, A Gilead Company | Trial completion date: Nov 2026 --> Mar 2041 | Trial primary completion date: Nov 2026 --> Mar 2041
Trial completion date • Trial primary completion date
|
Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • KITE-222 • KITE-363 • KITE-439 • KITE-585 • KITE-718
over2years
Study Evaluating the Safety and Efficacy of KITE-363 in Participants With Relapsed and/or Refractory B-cell Lymphoma (clinicaltrials.gov)
P1, N=80, Recruiting, Kite, A Gilead Company | Trial primary completion date: Jan 2026 --> Feb 2024
Trial primary completion date • CAR T-Cell Therapy
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • CSF2 (Colony stimulating factor 2) • GZMB (Granzyme B) • GZMA (Granzyme A) • IL17A (Interleukin 17A) • IL15 (Interleukin 15) • IL1R1 (Interleukin 1 receptor, type I) • IL7 (Interleukin 7) • CRP (C-reactive protein)
|
cyclophosphamide • fludarabine IV • KITE-363
3years
Study Evaluating the Safety and Efficacy of KITE-363 in Participants With Relapsed and/or Refractory B-cell Lymphoma (clinicaltrials.gov)
P1, N=80, Recruiting, Kite, A Gilead Company | Not yet recruiting --> Recruiting
Clinical • Enrollment open • CAR T-Cell Therapy
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • CSF2 (Colony stimulating factor 2) • GZMB (Granzyme B) • GZMA (Granzyme A) • IL17A (Interleukin 17A) • IL1R1 (Interleukin 1 receptor, type I) • CRP (C-reactive protein)
|
cyclophosphamide • fludarabine IV • KITE-363
over3years
Study Evaluating the Safety and Efficacy of KITE-363 in Participants With Relapsed and/or Refractory B-cell Lymphoma (clinicaltrials.gov)
P1, N=80, Not yet recruiting, Kite, A Gilead Company
Clinical • New P1 trial • CAR T-Cell Therapy
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • CSF2 (Colony stimulating factor 2) • GZMB (Granzyme B) • GZMA (Granzyme A) • IL17A (Interleukin 17A) • IL1R1 (Interleukin 1 receptor, type I) • CRP (C-reactive protein)
|
fludarabine IV • KITE-363 • cyclophosphamide intravenous
Share via
